Why the promise comes before the caveat
A supplement can advertise that it “supports” sleep, digestion, or immune function without first proving to the Food and Drug Administration that it treats a disease. These are generally called structure/function claims: they describe an effect on the body’s normal structures or processes, rather than claiming to diagnose, cure, or prevent a specific illness.
The familiar disclaimer—“These statements have not been evaluated by the Food and Drug Administration”—marks that distinction. It is required when companies make this kind of claim. It does not mean the FDA has tested the product and found the claim false; it means the agency did not evaluate the claim before the product went on sale.
A different route to market
Unlike prescription drugs, dietary supplements generally do not need FDA approval for safety and effectiveness before sale. Companies are responsible for making sure their products are safe and their labeling is lawful. The FDA can act against unsafe products or misleading labels, but that oversight is largely a matter of monitoring products on the market and responding to problems—not approving each bottle in advance.
That arrangement lowers the barrier to selling a new supplement. A company can present a benefit in familiar, appealing language while the fine-print disclaimer signals that the benefit has not been independently assessed by the FDA. The disclaimer is not permission to make any claim: disease-treatment claims face stricter rules, and advertising must not be deceptive.
What the label can—and cannot—tell you
The front label is designed to communicate a possible benefit quickly; the disclaimer describes the limits of regulatory review. Neither, by itself, establishes that a supplement works for a particular person. The caveat is about who evaluated the claim, not a verdict on whether the product is effective. That distinction is why a hopeful promise and a regulatory disclaimer can legally appear on the same package.
